Dr Reddy's Q4 net profit seen at Rs 448cr, up 34% YoY

Dr Reddy's Laboratories is expected to report a 34 percent YoY increase in net profit to Rs 448 crore for the fourth quarter, according to an ET Now poll. Net sales is expected to rise to Rs 2,601 crore.

Highlights:

Net sales seen at Rs 2,601 crore vs Rs 2,017 crore, up 29% YoY
Net profit seen at Rs 448 crore vs Rs 334 crore, up 34% YoY
EBITDA seen at Rs 680 crore vs Rs 430 crore, up 58% YoY
Margins seen at 26.2% vs 21.3%

Key Factors:

US business will be key growth driver for revenues
Zyprexa Generic and Geodon exclusivity will boost US revenues
Zyprexa revenues expected at Rs 220 crore, Geodon revenues at Rs 65 crore
Sustained growth expected in Russian OTC business
Subdued growth seen in domestic formulations business
Margins to be boosted by contribution from Zyprexa and Geodon